Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Scynexis Inc (NQ: SCYX )

2.415 -0.075 (-3.01%)
Streaming Delayed Price Updated: 12:49 PM EDT, Jun 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Scynexis Inc

< Previous 1 2 3 Next >
WBB Research Institute Webcast Highlighted the Need For a Global Response to Candida auris and Other Deadly Antimicrobial Resistant Pathogens
Cranford, New Jersey--(Newsfile Corp. - May 19, 2023) - WBB Research Institute (WBBRI) hosted... 
Via Newsfile
SCYNEXIS: Q1 Earnings Insights
 
Via Benzinga
Looking Into SCYNEXIS's Return On Capital Employed
 
Via Benzinga
Dow Rises 100 Points; Accelerate Diagnostics Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 100 points on Thursday. The Dow traded up 0.31% to 32,819.16 while the NASDAQ rose 0.63% to 12,001.83. The S&P... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Scynexis Inc. (NASDAQ: SCYX) Leading the Way in Thursday Trading Based on Percentage Gain
Via Investor Brand Network
GSK Bets On Scynexis' FDA-Approved Antifungal Drug For Over $500M In Bio Bucks
 
Via Benzinga
SCYNEXIS's Return On Capital Employed Overview
 
Via Benzinga
Why Bed Bath & Beyond Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers SCYNEXIS, Inc. (NASDAQ: SCYX) shares climbed 68% to $2.8184 after the company announced an exclusive license agreement with GSK for Brexafemme, in which the company will receive an upfront... 
Via Benzinga
SCYNEXIS (NASDAQ: SCYX) Enters Into Exclusive Agreement with GSK (NYSE: GSK) to Continue Commercializing Brexafemme to Treat Fungal Infections
SCYNEXIS, Inc. (NASDAQ: SCYX) operates as a biotechnology company, which is focused on the research and development of novel solutions 
Via Spotlight Growth
Scynexis Looks For Commercial Partner For Its Lead Infection Treatment
 
Via Benzinga
Warner Music Layoffs: What to Know About the Latest WMG Job Cuts
Warner Music (WMG) layoffs have the entertainment company cutting 4% of its workforce, or 270 jobs, during economic uncertainty. 
Via InvestorPlace
Why Is EVgo (EVGO) Stock Up 25% Today?
EVgo (EVGO) stock is on the rise Thursday following the release of its earnings report for the fourth quarter of the year! 
Via InvestorPlace
Why Is Scynexis (SCYX) Stock Up 69% Today?
Scynexis (SCYX) stock is taking off on Tuesday as investors react to news of an exclusive license agreement for Brexafemme. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Why Edible Garden Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) shares jumped 69.6% to $15.01 after dropping 24% on Tuesday. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Analyst Sees Multiple Chances With Over 300% Upside Potential For This Fungal Infections Stock
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the week with an overview of the biggest pre-market stock movers traders need to know about for Monday! 
Via InvestorPlace
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 75 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 258 companies hit new 52-week lows. 
Via Benzinga
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the... 
Via Benzinga
Looking Into SCYNEXIS's Return On Capital Employed
Benzinga Pro data, SCYNEXIS (NASDAQ:SCYX) reported Q2 sales of $1.32 million. Earnings fell to a loss of $13.35 million, resulting in a 144.82% decrease from last quarter. 
Via Benzinga
Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary
 
Via Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga
Earnings Scheduled For August 15, 2022
Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is likely to report earnings for its second quarter. 
Via Benzinga
SCYNEXIS Shares Climb As FDA Accepts Filing For Vaginal Yeast Infection Candidate Under Priority Review
SCYNEXIS (NASDAQ: SCYX) announced that the U.S. Food and Drug Administration (FDA) has accepted its submission of a supplemental New Drug Application (sNDA) to expand the label of BREXAFEMME... 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.